Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-daclizumab and pentetic acid calcium in Adult T-Cell Leukemia
NCT00019227Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 1996
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of yttrium-90 anti-Tac antibody in adult T-cell leukemia/lymphoma (ATLL), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose, Therapeutic Efficacy and 1 more. Started Oct 1996; status: completed.
02
Drugs
yttrium-90 anti-Tac antibody
03
Conditions
adult T-cell leukemia/lymphoma (ATLL)
Beyond the preview
Go deeper on NCT00019227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019227.